Literature DB >> 12093141

Lithium neurotoxicity: the development of irreversible neurological impairment despite standard monitoring of serum lithium levels.

Emma J Lang1, Stephen M Davis.   

Abstract

We report the case of a 44 year old man who presented with a two-month history of dysarthria, ataxia and leg weakness whilst on maintenance lithium for bipolar disorder. Examination revealed significant cerebellar and pyramidal dysfunction. Serum lithium was 1.5 mmol/l, a moderate elevation above his usual stable levels of 0.4-0.8 mmol/l. The patient's past history included hypertension and chronic renal impairment and the development of neurological symptoms coincided with the recent onset of heart failure. On cessation of lithium he partially recovered, the main residuum being persistent cerebellar ataxia. The case is an example of lithium neurotoxicity developing insidiously in the absence of an overt acute phase syndrome, and highlights the need for keen observation of the patient in the hope of preventing permanent deficits. Copyright 2002 Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093141     DOI: 10.1054/jocn.2001.0977

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.

Authors:  Cengiz Tuglu; Esin Erdogan; Ercan Abay
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

3.  Assessment of Ethanol-Induced Toxicity on iPSC-Derived Human Neurons Using a Novel High-Throughput Mitochondrial Neuronal Health (MNH) Assay.

Authors:  Annika Zink; Josefin Conrad; Narasimha Swami Telugu; Sebastian Diecke; Andreas Heinz; Erich Wanker; Josef Priller; Alessandro Prigione
Journal:  Front Cell Dev Biol       Date:  2020-11-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.